Edition:
United Kingdom

Morphosys AG (MORG.DE)

MORG.DE on Xetra

75.00EUR
10:48am GMT
Change (% chg)

€0.08 (+0.11%)
Prev Close
€74.92
Open
€75.00
Day's High
€76.38
Day's Low
€74.85
Volume
36,569
Avg. Vol
179,364
52-wk High
€83.83
52-wk Low
€46.05

Latest Key Developments (Source: Significant Developments)

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

Morphosys Increases Financial Guidance For 2017
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - MORPHOSYS AG ::INCREASES FINANCIAL GUIDANCE FOR 2017 FOLLOWING SIGNATURE OF REGIONAL LICENSE AGREEMENT FOR ANTIBODY MOR202 WITH I-MAB.‍FOR YEAR 2017, MORPHOSYS NOW EXPECTS REVENUES IN RANGE FROM EUR 63 TO 66 MILLION​.NOW EXPECTS FY EBIT OF EUR -66 TO -71 MILLION (UP FROM PREVIOUSLY EUR -75 TO -85 MILLION).FY ‍PROPRIETARY RESEARCH AND DEVELOPMENT EXPENSES WILL BE IN RANGE FROM EUR 96 TO 100 MILLION (PREVIOUSLY EUR 85 TO 95 MILLION)​.RECEIVES AN IMMEDIATE UPFRONT PAYMENT OF USD 20 MILLION FROM LICENSE AGREEMENT SIGNED.WILL BE ENTITLED TO RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM I-MAB OF UP TO C. USD 100 MILLION.TO BE ENTITLED TO RECEIVE TIERED, DOUBLE-DIGIT ROYALTIES ON NET SALES OF MOR202 IN TERRITORY.SHARES JUMP 5.2 PERCENT​.  Full Article

Janssen receives approval for Tremfya in Europe - Morphosys
Thursday, 23 Nov 2017 

Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is ‍entitled to royalties on net sales of Janssen's Tremfya​.  Full Article

Morphosys Q3 revenue up 20 pct at 15 mln eur​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Morphosys AG :Q3 net loss -24 million eur versus -12.8 million eur loss year ago.Q3 revenue rose 20 percent to 15 million eur.Says ‍group revenue for q3 2017 up 20% to eur 15.0 million (q3 2016: eur 12.5 million)​.Says Dr. Markus Enzelberger, interim CSO, now appointed CSO​.Says ‍company confirms financial guidance​.Says ‍earnings before interest and taxes (ebit) in q3 2017 amounted to eur -23.5 million (q3 2016: eur -13.1 million)​.  Full Article

Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Morphosys AG -:DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL.Morphosys AG says ‍receives FDA breakthrough therapy designation for its antibody MOR208 in relapsed/refractory DLBCL​.  Full Article

Morphosys starts Phase 2 trial of MOR208 in combination with idelalisib
Tuesday, 13 Dec 2016 

Morphosys Ag :Morphosys starts Phase 2 trial of MOR208 in combination with idelalisib in patients with relapsed or refractory CLL or SLL previously treated with a BTK inhibitor.  Full Article

Morphosys sees FY 2016 revenue eur 47-52 million
Monday, 1 Aug 2016 

Morphosys Ag :Sees fy 2016 revenue eur 47 million to eur 52 million.  Full Article

Morphosys H1 EBIT at -19.2 mln eur
Monday, 1 Aug 2016 

Morphosys Ag : Says group revenue in first half of 2016 totaled eur 24.3 million and EBIT amounted to eur -19.2 million . Says group's liquidity position on june 30, 2016 equaled eur 279.7 million (December 31, 2015: eur 298.4 million) .Says company confirms its 2016 guidance for revenue in range of eur 47 million to eur 52 million and EBIT between eur -58 million and eur -68 million..  Full Article

Morphosys AG confirms FY 2016 guidance
Tuesday, 3 May 2016 

Morphosys AG:Says confirmed its 2016 financial year guidance for revenue in range of 47 million euros to 52 million euros and EBIT loss in range of 58 million euros to 68 million euros.FY 2016 revenue estimate 49.01 million euros - Thomson Reuters I/B/E/S.FY 2016 EBIT loss estimate 66.5 million euros - Thomson Reuters I/B/E/S.  Full Article

Morphosys says Phase 2b/3 of bimagrumab fails to reach goal
Thursday, 21 Apr 2016 

Morphosys AG:Partner Novartis has confirmed that a phase 2b/3 study of bimagrumab did not meet its primary endpoint.Data are currently being reviewed and will inform decisions on bimagrumab development program.Ongoing clinical trials are not being discontinued at this time.  Full Article

German stocks - Factors to watch on December 12

FRANKFURT/BERLIN, Dec 12 The following are some of the factors that may move German stocks on Tuesday: